

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-9. (Canceled)

10. (Currently Amended) An isolated, enriched or purified ALK-7 polypeptide comprising:

- (a) the full length amino acid sequence set forth in SEQ ID NO: 2,
- (b) an amino acid sequence that is at least 95% identical to the amino acid sequence set forth in SEQ ID NO: 2,
- (c) the catalytic domain encoded by amino acid residues 193-485 of SEQ ID NO: 2, or
- (d) the cytoplasmic domain encoded by amino acid residues 137-493 of SEQ ID NO: 2,

wherein said ALK-7 polypeptide has kinase catalytic activity.

11-22. (Canceled)

23. (Previously Presented) The ALK-7 polypeptide of claim 10, having an amino acid sequence that is at least 95% identical to the sequence of SEQ ID NO: 2.

24. (Previously Presented) The ALK-7 polypeptide of claim 10, comprising the catalytic domain encoded by amino acid residues 193-485 of SEQ ID NO: 2.

25. (Canceled)

26. (Previously Presented) The polypeptide of claim 10, further comprising a second polypeptide fused to said ALK-7 polypeptide.

27. (Previously Presented) The polypeptide of claim 26, wherein said second polypeptide is GST.

28. (Currently Amended) An isolated, enriched or purified ~~The~~ ALK-7 polypeptide of ~~claim 10~~, comprising the full length amino acid sequence set forth in SEQ ID NO: 2.

29. (Previously Presented) The ALK-7 polypeptide of claim 10, comprising the cytoplasmic domain encoded by amino acid residues 137-493 of SEQ ID NO: 2.